药理应激光学扫描使用2-环基甲基立基氨酸 (WRC-0470). 一种新型的,短效的腺A2A受体激动剂
1Department of Medicine, University of Virginia Health Sciences Center, Charlottesville 22908, USA. dkg2w@virginia.edu
Circulation
|October 1, 1996
概括
一种新的选择性腺A2A受体激动剂,WRC-0470,有效地扩大冠状动脉用于压力成像,而不会引起副作用. 这为接受药理应力测试的患者提供了更安全的替代方案.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 医疗成像医学成像
背景情况:
- 药理应激成像剂如腺因非选择性腺受体刺激而导致显著的副作用.
- 这些副作用包括低血压,胸痛和支气管,限制了它们在某些患者的使用.
研究的目的:
- 评价一种新型的,选择性腺A2A受体激动剂 (WRC-0470) 作为药理学压力输液成像的潜在药剂.
- 确定WRC-0470是否可以诱导冠状动脉血管扩张,而不会产生与非选择性腺受体激动剂相关的不良影响.
主要方法:
- 给开放胸部的狗服用WRC-0470,评估与剂量相关的冠状动脉血管扩张和血液动力学稳定性.
- 比较WRC-0470的血液动力学反应和冠状动脉血管扩张与诱导冠状动脉狭窄症的狗中的腺素.
- 在峰值应力下使用201T1注射用于输液成像,以评估心肌缺陷.
主要成果:
- WRC-0470在左前下降 (LAD) 和左环 (LCx) 冠状动脉中产生剂量依赖的血管扩张,而不会影响心率或血压.
- 氨酸的使用导致显著的低血压,限制了其使用.
- 在没有低血压的情况下,WRC-0470显著增加了LCx血液流动, perfusion成像显示了LAD狭窄症的狗的肠膜缺陷.
结论:
- 选择性腺A2A激动剂WRC-0470是一种强效,短效的冠状动脉血管扩张剂.
- WRC-0470证明了作为药理学压力输液成像的安全有效药剂的潜力.
相关概念视频
Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Agonists: Direct-Acting Agents
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
Adrenergic Agonists: Therapeutic Uses
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...


